Your trusted source for investing success

Tag: novartis

Are You Aware of the FDA's Plans for 2018?

Find out what's going on in our new report
 
What Is In-Licensing?

What Is In-Licensing?

Licensing deals might be pharma’s preferred mode of business development these days—perhaps even more so than outright acquisitions.

Novartis receives FDA approval for Cosentyx label update to include moderate-to-severe scalp psoriasis

Novartis (VTX: NOVN) announced that the US Food and Drug Administration (FDA) has approved a label update for Cosentyx® (secukinumab), the first interleukin-17A (IL-17A) inhibitor approved to treat moderate-to-severe plaque psoriasis. The updated label includes Cosentyx data in moderate-to-severe scalp psoriasis – one of the difficult-to-treat forms of the disease, which

Novartis Advanced Accelerator Applications Receives FDA Approval for Lutathera

Novartis (NYSE: NVS) announced that Advanced Accelerator Applications, a subsidiary of Novartis Groupe S.A., has received US Food and Drug Administration approval of its new drug application for Lutathera® (lutetium Lu 177 dotatate*) for the treatment of somatostatin receptor positive gastroenteropancreatic neuroendocrine tumors, including foregut, midgut, and hindgut neuroendocrine tumors, in

Advanced Accelerator Applications Receives US FDA Approval for LUTATHERA

Advanced Accelerator Applications (NASDAQ:AAAP) a Novartis company and leader in nuclear medicine theragnostics, today announced that  it has received US Food and Drug Administration approval of its new drug application (NDA) for LUTATHERA® (lutetium Lu 177 dotatate) for the treatment of somatostatin receptor positive gastroenteropancreatic neuroendocrine tumors.

As quoted in the press release:
NETs

Novartis Releases Fourth Quarter and Full Year Financials

Novartis (NYSE:NVS) delivered good operational performance and landmark innovation in 2017, entering our next growth phase.
As quoted in the release:

Vas Narasimhan, designated CEO from February 1, commented:
“I want to thank Joe and the Board for their leadership and guidance as I transition to my new role. As CEO my priorities

Top Pharmaceutical ETFs

Top Pharmaceutical ETFs

To help make investors aware of some of their options when looking at investing in the pharmaceutical sector, the Investing News Network took a look at the five top pharmaceutical ETFs.

Are You Aware of the FDA's Plans for 2018?

Find out what's going on in our new report
 
Enter Your Log In Credentials
This setting should only be used on your home or work computer.

×

Privacy & Legal Policy

Privacy Policy

×
Investing News Network

Send this to a friend

Hi,
I thought you might find this interesting:
What Is In-Licensing?

URL: https://investingnews.com/daily/life-science-investing/pharmaceutical-investing/what-is-in-licensing/